StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Aesthetics Portfolio by Year

Aesthetics Portfolio — International operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

AbbVie Aesthetics Portfolio: -1.5% in FY2025, up 1.0 pts from a year earlier.

Latest, FY2025
-1.5%
Period ended Dec 31, 2025
Change on a year earlier
+1.0 pts
-2.5% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

“|| Aesthetics | 2,990 | 1,870 | 4,860 | (8.5) | (2.0) | (6.1) | (1.5) | (5.9)”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAesthetics Portfolio — International operational (constant-currency) growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 2025-1.5%+1.0 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
FY2024Dec 31, 2024-2.5%-8.6 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
FY2023Dec 31, 20236.1%-9.5 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
FY2022Dec 31, 202215.6%-29.1 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
FY2021Dec 31, 202144.7%+61.2 ptsForm 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
FY2020Dec 31, 2020-16.5%–Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗

Cite this data

StockData. (2026). AbbVie Aesthetics Portfolio (%), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-aesth-intl-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.